Our lead program is a best-in-class positive allosteric modulator (PAM) that targets the α5-GABA-A receptor.

Cognitive deficits—impairments in the ability to
understand, remember, and think clearly—
result from loss of connections between brain cells.

Damona is developing therapies that restore contacts between brain cells to reverse cognitive impairment and improve life for the significant number of patients living with cognitive deficits.

Damona is focused on discovering and developing precision neuromedicines for patients living with cognitive deficits associated with psychiatric and neurodegenerative disorders such as depression, Alzheimer’s disease, and schizophrenia.

Our lead drug is the first potential precision medicine approach for the treatment of cognitive impairment associated with major depressive disorder (MDD) by targeting a specific subunit of the GABA-A receptor to improve its function.

Cognitive deficits such as memory loss, concentration, and problem-solving are prevalent across CNS disorders—yet there are no medications to treat their devastating symptoms. Damona’s founder discovered a pivotal “weak link” in a brain pathway that is dysfunctional across some of the most common brain disorders and demonstrated that damage to this pathway contributes to cognitive deficits. This breakthrough has unlocked a new precision medicine approach to restore contacts between neurons and reverse cognitive deficits. Our goal is to enable the millions of people suffering from cognitive deficits associated with psychiatric and neurodegenerative disorders to function more proficiently and fully in their daily lives.